insights_auto
Why is 524494 down 3,51%?
Dive Deeperchevron_right
524494:BOM
IPCA Laboratories Ltd
₹1.845,00
arrow_downward
-3,51%(-67,20) 1D
16 ຕ.ລ., 15 ໂມງ 30 ນາທີ 00 ວິນາທີ GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 524494...
Open
₹1.913,95
High
₹1.913,95
Low
₹1.812,60
Mkt. cap
468,21 ຕື້
Avg. vol.
27,90 ພັນ
Volume
12,00 ພັນ
Dividend
0,33%
Quarterly dividend
₹1,50
Ex-dividend date
7 ສ.ຫ. 2026
P/E ratio
35,74
52-wk high
₹2.039,30
52-wk low
₹1.252,95
EPS
₹51,63
Shares outstanding
126,35 ລ້ານ
No. of employees
17 ພັນ
Open
₹1.913,95
High
₹1.913,95
Low
₹1.812,60
Mkt. cap
468,21 ຕື້
Avg. vol.
27,90 ພັນ
Volume
12,00 ພັນ
Dividend
0,33%
Quarterly dividend
₹1,50
Ex-dividend date
7 ສ.ຫ. 2026
P/E ratio
35,74
52-wk high
₹2.039,30
52-wk low
₹1.252,95
EPS
₹51,63
Shares outstanding
126,35 ລ້ານ
No. of employees
17 ພັນ
News stories
From web sources and news partners
The Motley Fool
·
45 ນາທີກ່ອນ
A Record Number of S&P 500 Companies Issued Upbeat Guidance Before Earnings Season. Should You Buy an Index Fund Now?
MarketBeat
·
59 ນາທີກ່ອນ
Fox Corporation (NASDAQ:FOX) Stock Has Average Price Target of $76.56
Simply Wall Street
·
1 ຊົ່ວໂມງກ່ອນ
What Pacira BioSciences Doubters Got Wrong
Yahoo Finance
·
22 ຊົ່ວໂມງກ່ອນ
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
Profile
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company manufactures and markets more than 350 finished-dosage formulations and around 80 active pharmaceutical ingredients, covering therapeutic areas that include pain management, rheumatology, antimalarials, cardiovascular medicine, dermatology and anti-diabetics, and has an emerging biosimilars business. Its products are sold in over 100 countries, and it is one of India's larger API exporters, supplying more than 70 countries.
Ipca is one of the largest global suppliers of the antimalarials hydroxychloroquine and chloroquine, as well as of APIs such as atenolol, chlorthalidone, losartan and metoprolol. Since 2023, it has held a majority stake in Unichem Laboratories. The company is listed on the BSE and the National Stock Exchange of India, and reported consolidated revenue of ₹9,646 crore in the financial year ended 31 March 2026. Wikipedia
About IPCA Laboratories Ltd